ERCC1 как маркёр резистентности рака яичников к препаратам платины
Аннотация
Обзор посвящён важнейшему маркёру эксцизионной репарации нуклеотидов ERCC1 и его вкладу в резистентность рака яичников к препаратам платины. Рассмотрены все варианты лабораторного и клинического определения ERCC1 в ткани рака яичников (однонуклеотидные полиморфизмы гена ERCC1, уровень мРНК и белка). Систематизированы сведения о прогностической и предиктивной значимости ERCC1 в качестве маркёра эффективности платиносодержащей терапии рака яичников. Авторы обсуждают возможные причины разнородности результатов и подчёркивают необходимость унифицированного и интегрального подхода к исследованию ERCC1 в опухоли. Проанализированы работы, цитированные в поисковой системе Pub Med до января 2015 года.
Ключевые слова
Об авторах
Т. А. Богуш
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
А. С. Попова
Факультет фундаментальной медицины МГУ им. М.В. Ломоносова
Россия
Россия
Е. А. Дудко
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
Е. А. Богуш
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
А. С. Тюляндина
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
С. А. Тюляндин
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
М. И. Давыдов
Российский онкологический научный центр им. Н.Н. Блохина
Россия
Россия
Список литературы
1. DeLoia J.A., Bhagwat N.R., Darcy K.M. et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecologic Oncology 2012; 126: 3: 448-454.
2. Syrios J., Banerjee S., Kaye S.B. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets - where are we now? Anticancer Research 2014; 34: 5: 2069-2077.
3. Cepeda V., Fuertes M.A., Castilla J. et al. Biochemical mechanisms of cisplatin cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2007; 7: 1: 3-18.
4. Pinto A.L., Lippard S.J. Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA. Biochimica et Biophysica Acta (BBA) Reviews on Cancer 1985; 780: 3: 167-180.
5. Zwelling L.A., Michaels S., Schwartz H. et al. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cisdiamminedichloroplatinum(II) and l-phenylalanine mustard. Cancer Research 1981; 41: 2: 640-649.
6. Plooy A.C.M., van Dijk M., Lohman P.H.M. Inductionand repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Research 1984; 44: 5: 2043-2051.
7. Bowden N.A. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Letters 346: 2: 163-171.
8. Atsushi H., Shuji S., Kosuke A., Takafumi K. A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. International J Biochemistry 1994; 26: 8: 1009-1016.
9. Almeida G.M., Duarte T.L., Farmer P.B. et al. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. International J Cancer 2008; 122: 8: 1810-1819.
10. Zeng-Rong N., Paterson J., Alpert L. et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Research 1995; 55: 21: 4760-4764.
11. Tripsianes K., Folkers G., Ab E. et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13: 12: 1849-1858.
12. Hansson J., Wood R.D. Repair synthesis by human cell extracts in DNA damaged by cis- and transdiamminedichloroplatinum(II). Nucleic Acids Research 1989; 17: 20: 8073-8091.
13. Westerveld A., Hoeijmakers J.H.J., van Duin M. et al. Molecular cloning of a human DNA repair gene. Nature 1984; 310: 5976: 425-429.
14. Jaspers N.G.J., Raams A., Silengo M.C. et al. First reported patient with human ERCC1 deficiency has cerebrooculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Amer J Human Genetics 2007; 80: 3: 457-466.
15. Gregg S.Q., Robinson A.R., Niedernhofer L.J. Physiological consequences of defects in ERCC1-XPF DNA repair endonuclease. DNA Repair 2011; 10: 7: 781-791.
16. Lee K.B., Parker R.J., Bohr V. et al. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993; 14: 10: 2177-2180.
17. Johnson S.W., Laub P.B., Beesley J.S. et al. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Research 1997; 57: 5: 850-856.
18. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60: 1305-1313.
19. Arora S., Kothandapani A., Tillison K. et al. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) 2010; 9: 745-753. 20.
20. De Silva I.U., McHugh P.J., Clingen P.H., Harley J.A. Defects in understand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Research 2002; 30: 17: 3848-3856.
21. Krivak T.C., Darcy K.M., Tian C. et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clinical Oncology 2008; 26: 21: 3598-3606.
22. Qi B.-l., Li Y., Wang N. et al. Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy. Zhonghua fu chan ke za zhi 2013; 48: 11: 847-852.
23. Kang S., Ju W., Kim J.W. et al. Association between excision repair crosscomplementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006; 38: 320-324.
24. Smith S., Su D., Rigault de la Longrais I. A. et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clinical Oncology 2007; 25: 33: 5172-5179.
25. Moxley K.M., Benbrook D.M., Queimado L. et al. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecologic Oncology 2013; 130: 2: 377-382.
26. Marsh S., Paul J., King C.R. et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clinical Oncology 2007; 25: 29: 4528-4535.
27. Dabholkar M., Vionnet J., Bostick-Bruton F. et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clinical Investigation 1994; 94: 2: 703-708.
28. Youn C.-K., Kim M.-H., Cho H.-J. et al. Oncogenic H-ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Research 2004; 64: 14: 4849-4857.
29. Xie C., Yin R.-t., Li Y.-l. et al. The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical Science Edition 2011; 42: 1: 86-89.
30. Steffensen K.D., Waldstrom M., Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. International Journal of Gynecological Cancer 2009; 19: 5: 820-825.
31. Stadlmann S., Singer G., Dirnhofer S. et al. ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecologic Oncology 2008; 108: 1: 252-253. 32.
32. Bösmüller H., Haitchi-Petnehazy S., Webersinke G. et al. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Archiv 2011; 459: 2: 183-191.
33. Kuhlmann J.D., Wimberger P., Bankfalvi A. et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clinical Chemistry 2014; 60: 10: 1282-1289.
34. Jakobsen J.N., Santoni-Rugiu E., Ravn J., Sørensen J.B. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. European J Cancer 2013; 49: 11: 2494-2503.
35. Colombo P.-E., Fabbro M., Theillet C. et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Critical Reviews in Oncology/Hematology 2014; 89: 2: 207-216.
36. Богуш Т.А., Попова А.С., Дудко Е.А. и др. Дискордантность статуса эстрогеновых рецепторов между первичным и метастатическим раком молочной железы - возможные причины и прогностическая значимость. Антибиотики и химиотер. 2013; 58: 7-8:11-18.
37. Богуш Т.А., Шатурова А.С., Дудко Е.А. и др. Количественная иммунофлуоресцентная оценка с использованием проточной цитофлуориметрии экспрессии эстрогеновых рецепторов β в солидных опухолях человека. Вестник Московского университета, Серия 2, Химия 2011; 52: 4: 305-312.
38. Богуш Т.А., Дудко Е.А., Семаков А.В. и др. Иммунофлуоресцентный анализ и оценка клинической значимости экспрессии ERCC1 в ткани рака яичников. Доклады академии наук 2014; 457: 4: 481-486.
39. Friboulet L., Olaussen K.A., Pignon J.-P. et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. New England Journal of Medicine 2013; 368: 12: 1101-1110.
40. Bhagwat N.R., Roginskaya V.Y., Acquafondata M.B. et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Research 2009; 69: 17: 6831-6838.
41. Vaezi A.E., Bepler G., Bhagwat N.R. et al. Choline phosphate cytidylyl-transferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer 2014; 120: 12: 1898-1907.
42. Bauman J.E., Austin M.C., Schmidt R. et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer 2013; 109: 8: 2096-2105.
43. Smith D.H., Fiehn A.-M.K., Fogh L. et al. Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. Sci Rep 2014; 4.
44. Rubatt J.M., Darcy K.M., Tian C. et al. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a gynecologic oncology group study. Gynecologic Oncology 2012; 125: 2: 421-426.
45. Muallem M.Z., Braicu I., Nassir M. et al. ERCC1 Expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. Anticancer Research 2014; 34: 1: 393-399.
46. Milovic-Kovacevic M., Srdic-Rajic T., Radulovic S. et al. Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian
Для цитирования:
Богуш Т.А., Попова А.С., Дудко Е.А., Богуш Е.А., Тюляндина А.С., Тюляндин С.А., Давыдов М.И. ERCC1 как маркёр резистентности рака яичников к препаратам платины. Антибиотики и Химиотерапия. 2015;60(3-4):42-50.
For citation:
Bogush T.A., Popova A.S., Dudko E.A., Bogush E.A., Tyulyandina A.S., Tyulyandin S.A., Davydov M.I. ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs. Antibiotics and Chemotherapy. 2015;60(3-4):42-50. (In Russ.)
Просмотров: 51
ISSN 0235-2990 (Print)
Послать статью по эл. почте 